{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:32:44Z","timestamp":1792146764061,"version":"4.4.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1053\/j.seminoncol.2011.11.002","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T18:52:02Z","timestamp":1327949522000},"page":"58-66","source":"Crossref","is-referenced-by-count":44,"title":["Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression"],"prefix":"10.1053","volume":"39","author":[{"given":"Thomas","family":"Ernst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2011.11.002_bib1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib5","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib6","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib8","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib9","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib10","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib11","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"European LeukemiaNet","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib16","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2009.006999","article-title":"Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials","volume":"94","author":"Silver","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.13529","article-title":"The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up","volume":"94","author":"Palandri","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib19","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib20","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib22","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","article-title":"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib","volume":"116","author":"Sherbenou","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib23","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib25","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib26","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib27","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib28","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants","volume":"103","author":"Skaggs","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib29","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib30","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib31","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib32","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib33","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib36","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib37","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib38","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2005.05606.x","article-title":"Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors","volume":"130","author":"Angstreich","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib40","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2004-08-3373","article-title":"Punish the parent not the progeny","volume":"105","author":"Elrick","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib41","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib42","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib43","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib44","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib45","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3324\/haematol.2009.006981","article-title":"A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib","volume":"94","author":"Ernst","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib47","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib48","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib49","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib50","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib52","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib53","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.leu.2403307","article-title":"Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography","volume":"18","author":"Deininger","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib54","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1373\/clinchem.2004.031112","article-title":"Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib","volume":"50","author":"Soverini","year":"2004","journal-title":"Clin Chem"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib55","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1373\/clinchem.2004.034801","article-title":"Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib","volume":"50","author":"Irving","year":"2004","journal-title":"Clin Chem"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib56","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1373\/clinchem.2004.047274","article-title":"Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients","volume":"51","author":"Sorel","year":"2005","journal-title":"Clin Chem"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib57","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.leukres.2008.01.010","article-title":"High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain","volume":"32","author":"Pol\u00e1kov\u00e1","year":"2008","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib58","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.leu.2404635","article-title":"High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations","volume":"21","author":"Vivante","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib59","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/leu.2008.183","article-title":"Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR","volume":"23","author":"Oehler","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib60","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00277-003-0690-5","article-title":"Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique","volume":"82","author":"Kreuzer","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib61","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/sj.leu.2403983","article-title":"Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL","volume":"19","author":"Gruber","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib62","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1038\/leu.2008.180","article-title":"Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR","volume":"22","author":"Pelz-Ackermann","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib63","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/leu.2008.97","article-title":"Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR)","volume":"22","author":"Preuner","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib64","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.12964","article-title":"ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib65","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib66","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1073\/pnas.86.17.6783","article-title":"Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia","volume":"86","author":"Ahuja","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib67","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.1073\/pnas.88.14.6293","article-title":"p53 in chronic myelogenous leukemia in acute phase","volume":"88","author":"Feinstein","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib68","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-07-102533","article-title":"RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance","volume":"111","author":"Roche-Lestienne","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib69","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood.V85.8.2013.bloodjournal8582013","article-title":"Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia","volume":"85","author":"Sill","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib70","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib71","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib72","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1182\/blood.V78.9.2178.2178","article-title":"Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia","volume":"78","author":"Towatari","year":"1991","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib73","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1182\/blood.V78.12.3259.3259","article-title":"Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia","volume":"78","author":"Ahuja","year":"1991","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib74","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/10428190009059278","article-title":"Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia","volume":"38","author":"Beck","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib75","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ng791","article-title":"BCR-ABL suppresses C\/EBPalpha expression through inhibitory action of hnRNP E2","volume":"30","author":"Perrotti","year":"2002","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib77","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood-2007-03-078303","article-title":"High levels of the BCR\/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C\/EBPalpha-driven myeloid differentiation","volume":"110","author":"Chang","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib78","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1073\/pnas.0508143103","article-title":"Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr\/abl-induced malignancy","volume":"103","author":"Wagner","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib79","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1182\/blood-2005-01-0210","article-title":"Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment","volume":"105","author":"Schultheis","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib80","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-642-01222-8_9","article-title":"Bosutinib","volume":"184","author":"Keller","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib82","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.leukres.2009.04.021","article-title":"Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy","volume":"33","author":"Beel","year":"2009","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2011.11.002_bib83","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutant BCR-ABL positive clones after cessation of tyrosine kinase inhibitor therapy","volume":"96","author":"Hanfstein","year":"2011","journal-title":"Haematologica"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775411002910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775411002910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T11:44:41Z","timestamp":1593603881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775411002910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0093775411002910"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2011.11.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}